60+ Presentations from Top Biopharma in 2025
AbbVie
Digital Transformation of Bioprocess Development Labs
Diana Bowley, PhD, Associate Director, CMC Data & Digital Strategy, Bioprocess Development, AbbVie, Inc.
Keynote Presentation: Analytical Development Challenges for a Diverse Product Portfolio
Ivan R. Correia, PhD, Senior Research Fellow & Head, Global Protein Sciences, AbbVie, Inc.
Exploring Mass Spectrometry Sample Preparation Strategies beyond Trypsin Digestion
Malika Godamudunage, PhD, Senior Scientist, AbbVie
Development of Glucocorticoid Receptor Modulator ADC for Inflammatory Diseases
Michael McPherson, PhD, Research Fellow, Antibody Drug Conjugates, Technology and Therapeutic Platforms, AbbVie
Enhancing Laboratory Analysis with Generative AI-Based Chatbot
Michail Vlysidis, PhD, Senior Engineer, AbbVie
Amgen
Understanding the Biosynthesis of Polymeric IgM to Explore Its Structure as a Multivalent Binder Modality
Haruki Hasegawa, PhD, Scientific Director, Discovery Protein Science, Amgen
AstraZeneca
A Novel Bivalent Bispecific Antibody Format for Infectious Diseases
Xiuling Li, PhD, Associate Director, Novel Multispecific Modalities, AstraZeneca
Incorporating in silico Developability and Immunogenicity Assessments during Early-Stage Discovery
Tony Pham, Scientist, Biologics Engineering & Developability, AstraZeneca
The Role of Protein Engineering in Developing New Innovative Modalities
Puja Sapra, PhD, Senior Vice President, Head R&D Biologics, Engineering and Oncology Targeted Discovery, AstraZeneca
Interpretable Machine Learning for Modeling Non-Specific Binding of Biologics
Valentin Stanev, PhD, Associate Principal Data Scientist, AstraZeneca
Predicting Subvisible Particle Formation of Monoclonal Antibodies Using Quartz Crystal Microbalance with Dissipation
Yibo Wang, PhD, Postdoctoral Fellow, Machine Learning, AstraZeneca
From High-Throughput Discovery to Automating Small- to Mid-Scale Antibody Production to Support the Ever-Growing Needs of AI/ML
Christopher Wassif, PhD, Director, Molecular Engineering & Antibody Technologies, AstraZeneca
Biogen
Lessons Learned during the Development of Maleimide-Conjugated ASO for Subsequent Functionalization
Zifan Li, PhD, Senior Scientist, Analytical Development, Biogen
Evaluation of Orthogonal Technologies for AAV Empty/Full Capsid Analysis
Dana Tribby, Scientist, Analytical Development & Gene Therapy Chemistry, Biogen
LC-MS Characterization of Polysorbates and Their Degradants
Linda Yi, Associate Director, Analytical Development, Biogen
Bristol Myers Squibb
Empowering Hybrid Scientists: Bridging Lab Expertise and Data Science, a Case Study of Developing an Automated ELN Data Quality Monitoring Tool
Dan (Cassie) Liu, Principal Statistician, Bristol Myers Squibb
Jason Parent, Scientist, Bioassay Development, Bristol Myers Squibb
Monitoring Degradation in ADCs by LC-MS
Mahalia Serrano, PhD, Principal Scientist, Biologics Development, Bristol-Myers Squibb
Democratizing Data Analysis through Automation
Sara Byers, PhD, Principal Scientist, Quantitative Sciences & Digital Transformation, Bristol-Myers Squibb
A Comprehensive and Holistic Characterization Strategy of Biotherapeutics to Enhance Product Quality and Process Control
Chris M. Chumsae, PhD, Associate Director, Analytical Development, Bristol-Myers Squibb
Accelerating High-Throughput Production through Functional Assessments of Bispecifics
Kristoff Homan, PhD, Senior Principal Scientist, Discovery Biotherapeutics, Bristol-Myers Squibb Company
Genentech
KEYNOTE PRESENTATION: Nonclinical Immunogenicity Risk Assessment and Mitigation for Bispecific Antibodies
Paul J. Carter, PhD, Genentech Fellow, Antibody Engineering, Genentech
Bispecific Anti-KLK5/7 for Netherton and Atopic Dermatitis
Cecilia Chiu, PhD, Scientist IV, Genentech, Inc.
Machine Learning-Guided Selection and Design Optimization of Chemically Stable Antibodies
Saeed Izadi, PhD, Senior Principal Scientist & Group Leader, Pharmaceutical Development, Genentech, Inc.
An Oral Antibody for Inflammatory Bowel Disease
James T. Koerber, PhD, Distinguished Scientist and Director, Antibody Engineering, Genentech, Inc.
Cystine-Knot Peptide Inhibitors of HTRA1 Bind to a Cryptic Pocket within the Active Site Region
Yanjie Li, PhD, Scientist 4, Peptide Therapeutics, Genentech Inc.
The Design and Optimization of Degrader-Antibody Conjugates
Stephanie M. Monson, PhD, Principal Scientist & Group Leader, Conjugation & Chemical Biology, Genentech Inc.
Closed-Form Test Functions for Biophysical Sequence Optimization Algorithms
Samuel Stanton, PhD, Machine Learning Scientist, Prescient Design, Computational Sciences, Genentech
Antibody Immunogenicity Risk Assessment with Pep2Vec
Will Thrift, PhD, Senior Artificial Intelligence Scientist, Genentech
Incorporating Molecular Mimicry Features to Identify Immunogenic Hotspots in Antibody Therapeutic Sequences
Patrick Wu, MD, PhD, Senior Scientist, Genentech
Gilead Sciences Inc.
Analytical Toolkit for Structural Characterization with Mass Spec
Simon Letarte, PhD, Director, Extended Structural Characterization, Gilead Sciences Inc.
Johnson & Johnson
KEYNOTE PRESENTATION: Multispecific T Cell Engagers for the Treatment of Hematological Malignancies
Ulrike Philippar, PhD, Senior Director and Head, Oncology and Discovery Hematological Malignancies, Johnson & Johnson Innovative Medicine
Unlocking the Future of Protein Production in the Age of AI and Automation: The MARS Platform from Concept to Pipeline
Pramisha Adhikari, PhD, Senior Principal Scientist, Biologics Discovery, Johnson & Johnson Innovative Medicine
Elucidation of CHO Cell Metabolism Using Multi-Omics
J. Castro, PhD, Senior Scientist, Cell Engineering & Analytical Sciences, Johnson & Johnson Innovative Medicine
FEATURED PRESENTATION: Clinical Biomarkers of Response to Ciltacabtagene Autoleucel in Patients with Relapse or Refractory Multiple Myeloma
Katherine Li, Bioinformatics Specialist, Bioinformatics, Johnson & Johnson Innovative Medicine
Characterization of Antibody siRNA Conjugates
Tun Liu, PhD, Senior Principal Scientist, Biophysics, Johnson & Johnson Innovative Medicine
Nipocalimab: A High-Affinity, Immunoselective FcRn Blocker as an Investigational Therapy for IgG-Driven Autoimmune and Alloimmune Diseases
Nilufer Seth, PhD, Senior Scientific Director and Head, Discovery, Autoantibody Portfolio and Maternal Fetal Disease Area, Johnson & Johnson Innovative Medicine
Merck
Optimization of High-Density HD-CHO Transient Protein Production for a Robust Early-Stage Material Generation
Sultan Ciftci-Yilmaz, PhD, Senior Scientist II, Protein Design & Production, Merck Research Labs
Pool-Based Screening in Pichia pastoris for Rapid Evaluation of Secreted Protein Production
Lauren T. Cordova, PhD, Senior Scientist, Merck & Co. Inc.
Mammalian Display to Secretion Switchable Libraries for Antibody Preselection and High-Throughput Functional Screening
Achim Doerner, PhD, Scientific Director, Antibody Discovery & Protein Engineering, Merck Healthcare KGaA, Darmstadt
In vitro and in vivo Characterization Strategies for Novel Conjugations
Mei Han, Principal Scientist, Pharmacokinetics, Dynamics, Metabolism and Bioanalytical (PDMB), Merck & Co., Inc.
Streamlining and Accelerating Drug Discovery: Powering by Automated Sample Preparation through an Orchestrated Automation System
Jing Ke, PhD, Associate Principal Scientist, Discovery Biologics, Merck
Leveraging Automation for Cell Culture and High-Throughput Protein Expression Screening
Andrea Partridge, PhD, Senior Scientist, Protein & Structural Chemistry, Merck & Co., Inc.
PROxAb Shuttle: A Plug & Play Solution for Targeted Antibody-Mediated Degrader Delivery
Hendrik Schneider, PhD, Principal Scientist, Merck KGaA, Darmstadt, Germany
Engineering Chimeric Antigen Receptor for mRNA CAR T
Huan Yang, PhD, Associate Principal Scientist, Discovery Biologics, Merck & Co. Inc.
Grabbing the Bull by the Horns: Engineering Options of Cattle-Derived Ultralong CDR-H3 Paratopes for the Generation of Novel Multifunctional Antibody Architectures
Stefan Zielonka, PhD, Senior Director, Global Head of Antibody Discovery and Protein Engineering (ADPE) Research and Development, Merck Healthcare KGaA; Professor, Biomolecular Immunotherapy, Technische Universität Darmstadt
Novartis
Exploring the Design of Selectively-Targeted Payloads with Quantitative Systems Pharmacology
Eshita Khera, PhD, Principal Scientist II, Modeling & Simulation & PK Sciences, Novartis BioMedical Research
Novo Nordisk
LLM Embedding Coupled with Shallow Machine Learning Predicts the Expression Level of mAb and VHH in Mammalian Cells
Rahmad Akbar, PhD, Senior Data Scientist, Antibody Design, Novo Nordisk
Enhancing Complex Molecule Quantification Using Digitalized and Automated Platforms
Andreas Hald, PhD, Manager, Research Bioanalysis, Novo Nordisk
Improved Antibody-Antigen Interaction Prediction Using Inverse Folding Latent Representations
Paolo Marcatili, PhD, Head, Antibody Design, Novo Nordisk
Pfizer
Reversible Chemical Modification of Antibodies: Modulating FcγR Binding to Maintain Anti-Tumor Activity and Mitigate Systemic Immune Activation
Philip N. Moquist, PhD, Scientist, Chemistry, Pfizer Oncology
Streamlining Science: The Role of the Digitally Enabled Scientist
Brett Rygelski, Scientist, Pharmaceutical Sciences, Pfizer
Regeneron
An Effective Workflow for Assessing Domain-Specific Charge Heterogeneity in Bispecific Antibodies
Kai-Ti Chang, PhD, Scientist, Protein Biochemistry, Regeneron
Combination Strategies to Enhance Anti-Tumor T Cell Responses
Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.
Roche
Total Recall: Boosting Memory T Cells with Co-Stimulatory Bispecifics
Koorosh Korfi, PhD, Biomarker and Experimental Medicine Leader, Early Biomarker Development Oncology, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich
Sanofi
Avoiding Pitfalls in ML Model Validation for Protein Design: The Importance of Data Splits
Norbert Furtmann, PhD, Head, Computational and High-Throughput Protein Engineering, Large Molecule Research, Sanofi
Rapid Affinity-Based Purification of Multispecific Antibodies Using Kappa Select and Protein L
Brian E. Hall, PhD, Distinguished Scientist, Large Molecule Research, Sanofi
Large Language Models for mRNA Design
Sven Jager, PhD, Lead, Computational Science, Sanofi Germany GmbH
Targeted Dual Selection to Optimize Transposon Stable Pool Generation of Multispecifics in Large Molecules Research
Julie Johnston, Scientist, Large Molecule Research, Sanofi
Automated Ultradilute Measurements of Self-Association for the Identification of Antibodies with Favorable High-Concentration Solution Properties
Marissa V. Labreck, PhD, Senior Scientist, Sanofi
Takeda Pharmaceuticals Inc.
AI/ML in Biologics Drug Design: From Current Innovations to Future Possibilities
Kallol Ray, PhD, Vice President & Head, Global Biologics, Takeda Pharmaceuticals Inc.
Immunogenicity Assessment in New Modality Development: T and B Epitope Prediction
Xiaobin Zhang, PhD, Associate Director, Takeda Pharmaceuticals